CONFORTI, FABIO
CONFORTI, FABIO
Dipartimento Scienze Biomediche
A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy
2018-01-01 Perrino, M; Bozzarelli, S; Zucali, Pa; De Pas, Tm; Simonelli, M; De Vincenzo, F; Conforti, F; Persico, P; Miggiano, C; Cordua, N; Cioffi, A; Sala, S; Sposta, Fm; Giordano, L; Santoro, A
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
2022-01-01 Vellano, Cp; White, Mg; Andrews, Mc; Chelvanambi, M; Witt, Rg; Daniele, Jr; Titus, M; Mcquade, Jl; Conforti, F; Burton, Em; Lastrapes, Mj; Ologun, G; Cogdill, Ap; Morad, G; Prieto, P; Lazar, Aj; Chu, Ys; Han, Gc; Khan, Maw; Helmink, B; Davies, Ma; Amaria, Rn; Kovacs, Jj; Woodman, Se; Patel, S; Hwu, P; Peoples, M; Lee, Je; Cooper, Za; Zhu, Hf; Gao, G; Banerjee, H; Lau, M; Gershenwald, Je; Lucci, A; Keung, Ez; Ross, Mi; Pala, L; Pagan, E; Segura, Rl; Liu, Q; Borthwick, Ms; Lau, E; Yates, Ms; Westin, Sn; Wani, K; Tetzlaff, Mt; Haydu, Le; Mahendra, M; Ma, Xy; Logothetis, C; Kulstad, Z; Johnson, S; Hudgens, Cw; Feng, Np; Federico, L; Long, Gv; Futreal, Pa; Arur, S; Tawbi, Ha; Moran, Ae; Wang, Lh; Heffernan, Tp; Marszalek, Jr; Wargo, Ja
Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E
2014-01-01 Catania, C; Conforti, F; Spitaleri, G; Barberis, M; Preda, L; Noberasco, C; Lazzari, C; Toffalorio, F; De Marinis, F; Manzotti, M; De Pas, Tm
Aprepitant use during chemotherapy and association with survival in women with early breast cancer
2025-01-01 Botteri, Edoardo; Hjorth, Sarah; Conforti, Fabio; Bagnardi, Vincenzo; Andreassen, Bettina K; Støer, Nathalie C; Bhargava, Sameer; Ursin, Giske; Gandini, Sara; Sloan, Erica K; Chang, Aeson
Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials A Systematic Review and Meta-analysis
2022-01-01 Pala, L; Sala, I; Oriecuia, C; De Pas, T; Queirolo, P; Specchia, C; Cocorocchio, E; Ferrucci, P; Patane, D; Saponara, M; Pennacchioli, E; Coppola, S; Viale, G; Giaccone, G; Gelber, Rd; Bagnardi, V; Conforti, F
Avelumab combined with axitinib for patients with advanced thymoma B3 and thymic carcinoma
2025-01-01 Conforti, Fabio; Pala, Laura; Catania, Chiara; Zucali, Paolo Andrea; Sala, Isabella; Perrino, Matteo; De Vincenzo, Fabio; Cordua, Nadia; Canzian, Jacopo; Tinterri, Benedetta; Governini, Emily; Bendoni, Marzia; Santoro, Armando; Giaccone, Giuseppe; De Pas, Tommaso Martino
Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors
2020-01-01 Cocorocchio, E; Martinoli, C; Gandini, S; Pala, L; Conforti, F; Stucchi, S; Mazzarol, G; Ferrucci, P
Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast
2020-01-01 Conforti, F; Pala, L; Rocco, Eg; Pagan, E; Bagnardi, V; Montagna, E; Peruzzotti, G; De Pas, Tm; Fumagalli, C; Pileggi, S; Pesenti, C; Marchini, S; Marchi, C; Sapino, A; Gelber, Rd; Viale, G; Colleoni, M; Goldhirsch, A
Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations
2021-01-01 Conforti, F; Pala, L; Pagan, E; Rocco, Eg; Bagnardi, V; Montagna, E; Peruzzotti, G; De Pas, T; Fumagalli, C; Pileggi, S; Pesenti, C; Marchini, S; Corso, G; Marchio, C; Sapino, A; Graffeo, R; Collet, L; Aftimos, P; Sotiriou, C; Piccart, M; Gelber, Rd; Viale, G; Colleoni, M; Goldhirsch, A
Boosting anticancer immunotherapy through androgen receptor blockade
2022-01-01 Pala, L; De Pas, T; Conforti, F
Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities
2025-01-01 Catania, Chiara; Cascetta, Priscilla; Russo, Alessandro; Governini, Emily; Bendoni, Marzia; Laffi, Alice; Piloni, Ilaria; Conforti, Fabio; Pala, Laura; Cocorocchio, Emilia; Ceresoli, Giovanni; Locatelli, Marzia; Laszlo, Daniele; Facella, Flaminia; De Pas, Tommaso
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
2018-01-01 Conforti, F; Pala, L; Bagnardi, V; De Pas, T; Martinetti, M; Viale, G; Gelber, Rd; Goldhirsch, A
Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study
2022-01-01 Conforti, F; Gronchi, A; Penel, N; Jones, Rl; Broto, Jm; Sala, I; Bagnardi, V; Napolitano, A; Pala, L; Pennacchioli, E; Catania, C; Queirolo, P; Grigani, G; Merlini, A; Stacchiotti, S; Comandone, A; Vincenzi, B; Quagliuolo, V; Bertuzzi, A; Boglione, A; Palassini, E; Baldi, Gg; Blay, Jy; Ryckewaert, T; Toulmonde, M; Italiano, A; Le Cesne, A; Ray-Coquard, I; Cruz, J; Hernandez-Leon, Cn; Trufero, Jm; Moura, Dd; Muniz, Nh; De Pas, T
Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy
2019-01-01 Tarantino, P; Zagami, P; Trillo, P; Conforti, F; Pala, L; Morganti, S; Ferraro, E; Viale, G; Duso, Ba; D'Amico, P; Marra, A; Trapani, D; De Pas, Tm
Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study
2025-01-01 Catania, C.; Liu, S. V.; Garassino, M.; Delmonte, A.; Scotti, V.; Cappuzzo, F.; Genova, C.; Russo, A.; Russano, M.; Bennati, C.; Colantonio, I.; Martini, S.; Pino, M.; Conforti, F.; Pala, L.; Minuti, G.; Citarella, F.; Olmetto, E.; Esposito, A.; Cascetta, P.; Di Lello, A.; De Pas, T.
Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature
2021-01-01 Pala, L; Conforti, F; Cocorocchio, E; Ferrucci, P; De Pas, Mt; Stucchi, S; Repetto, M; Saponara, M; Queirolo, P
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity
2018-01-01 Rao, Gh; Kim, Ik; Conforti, F; Liu, J; Zhang, Yw; Giaccone, G
Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19
2020-01-01 Pala, L; Conforti, F; Saponara, M; De Pas, T; Giugliano, F; Sale, Eo; Jemos, C; Rubatto, M; Agostini, A; Quaglino, P; Fava, P; Fierro, Mt; Queirolo, P
Different Response to Immunotherapy According to Melanoma Histologic Subtype
2022-01-01 Pala, L; Conforti, F; Pagan, E; Bagnardi, V; De Pas, Tm; Mazzarol, G; Barberis, M; Pennacchioli, E; Orsolini, G; Prestianni, P; Zagami, P; Nicolo', E; Patane, D; Saponara, M; Queirolo, P
Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy
2022-01-01 Corti, C; Conforti, F; Pala, L; Catania, C; Cocorocchio, E; Ferrucci, Pf; Curigliano, G; Queirolo, P; De Pas, T
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy | 1-gen-2018 | Perrino, M; Bozzarelli, S; Zucali, Pa; De Pas, Tm; Simonelli, M; De Vincenzo, F; Conforti, F; Persico, P; Miggiano, C; Cordua, N; Cioffi, A; Sala, S; Sposta, Fm; Giordano, L; Santoro, A | |
| Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy | 1-gen-2022 | Vellano, Cp; White, Mg; Andrews, Mc; Chelvanambi, M; Witt, Rg; Daniele, Jr; Titus, M; Mcquade, Jl; Conforti, F; Burton, Em; Lastrapes, Mj; Ologun, G; Cogdill, Ap; Morad, G; Prieto, P; Lazar, Aj; Chu, Ys; Han, Gc; Khan, Maw; Helmink, B; Davies, Ma; Amaria, Rn; Kovacs, Jj; Woodman, Se; Patel, S; Hwu, P; Peoples, M; Lee, Je; Cooper, Za; Zhu, Hf; Gao, G; Banerjee, H; Lau, M; Gershenwald, Je; Lucci, A; Keung, Ez; Ross, Mi; Pala, L; Pagan, E; Segura, Rl; Liu, Q; Borthwick, Ms; Lau, E; Yates, Ms; Westin, Sn; Wani, K; Tetzlaff, Mt; Haydu, Le; Mahendra, M; Ma, Xy; Logothetis, C; Kulstad, Z; Johnson, S; Hudgens, Cw; Feng, Np; Federico, L; Long, Gv; Futreal, Pa; Arur, S; Tawbi, Ha; Moran, Ae; Wang, Lh; Heffernan, Tp; Marszalek, Jr; Wargo, Ja | |
| Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E | 1-gen-2014 | Catania, C; Conforti, F; Spitaleri, G; Barberis, M; Preda, L; Noberasco, C; Lazzari, C; Toffalorio, F; De Marinis, F; Manzotti, M; De Pas, Tm | |
| Aprepitant use during chemotherapy and association with survival in women with early breast cancer | 1-gen-2025 | Botteri, Edoardo; Hjorth, Sarah; Conforti, Fabio; Bagnardi, Vincenzo; Andreassen, Bettina K; Støer, Nathalie C; Bhargava, Sameer; Ursin, Giske; Gandini, Sara; Sloan, Erica K; Chang, Aeson | |
| Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials A Systematic Review and Meta-analysis | 1-gen-2022 | Pala, L; Sala, I; Oriecuia, C; De Pas, T; Queirolo, P; Specchia, C; Cocorocchio, E; Ferrucci, P; Patane, D; Saponara, M; Pennacchioli, E; Coppola, S; Viale, G; Giaccone, G; Gelber, Rd; Bagnardi, V; Conforti, F | |
| Avelumab combined with axitinib for patients with advanced thymoma B3 and thymic carcinoma | 1-gen-2025 | Conforti, Fabio; Pala, Laura; Catania, Chiara; Zucali, Paolo Andrea; Sala, Isabella; Perrino, Matteo; De Vincenzo, Fabio; Cordua, Nadia; Canzian, Jacopo; Tinterri, Benedetta; Governini, Emily; Bendoni, Marzia; Santoro, Armando; Giaccone, Giuseppe; De Pas, Tommaso Martino | |
| Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors | 1-gen-2020 | Cocorocchio, E; Martinoli, C; Gandini, S; Pala, L; Conforti, F; Stucchi, S; Mazzarol, G; Ferrucci, P | |
| Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast | 1-gen-2020 | Conforti, F; Pala, L; Rocco, Eg; Pagan, E; Bagnardi, V; Montagna, E; Peruzzotti, G; De Pas, Tm; Fumagalli, C; Pileggi, S; Pesenti, C; Marchini, S; Marchi, C; Sapino, A; Gelber, Rd; Viale, G; Colleoni, M; Goldhirsch, A | |
| Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations | 1-gen-2021 | Conforti, F; Pala, L; Pagan, E; Rocco, Eg; Bagnardi, V; Montagna, E; Peruzzotti, G; De Pas, T; Fumagalli, C; Pileggi, S; Pesenti, C; Marchini, S; Corso, G; Marchio, C; Sapino, A; Graffeo, R; Collet, L; Aftimos, P; Sotiriou, C; Piccart, M; Gelber, Rd; Viale, G; Colleoni, M; Goldhirsch, A | |
| Boosting anticancer immunotherapy through androgen receptor blockade | 1-gen-2022 | Pala, L; De Pas, T; Conforti, F | |
| Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities | 1-gen-2025 | Catania, Chiara; Cascetta, Priscilla; Russo, Alessandro; Governini, Emily; Bendoni, Marzia; Laffi, Alice; Piloni, Ilaria; Conforti, Fabio; Pala, Laura; Cocorocchio, Emilia; Ceresoli, Giovanni; Locatelli, Marzia; Laszlo, Daniele; Facella, Flaminia; De Pas, Tommaso | |
| Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis | 1-gen-2018 | Conforti, F; Pala, L; Bagnardi, V; De Pas, T; Martinetti, M; Viale, G; Gelber, Rd; Goldhirsch, A | |
| Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study | 1-gen-2022 | Conforti, F; Gronchi, A; Penel, N; Jones, Rl; Broto, Jm; Sala, I; Bagnardi, V; Napolitano, A; Pala, L; Pennacchioli, E; Catania, C; Queirolo, P; Grigani, G; Merlini, A; Stacchiotti, S; Comandone, A; Vincenzi, B; Quagliuolo, V; Bertuzzi, A; Boglione, A; Palassini, E; Baldi, Gg; Blay, Jy; Ryckewaert, T; Toulmonde, M; Italiano, A; Le Cesne, A; Ray-Coquard, I; Cruz, J; Hernandez-Leon, Cn; Trufero, Jm; Moura, Dd; Muniz, Nh; De Pas, T | |
| Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy | 1-gen-2019 | Tarantino, P; Zagami, P; Trillo, P; Conforti, F; Pala, L; Morganti, S; Ferraro, E; Viale, G; Duso, Ba; D'Amico, P; Marra, A; Trapani, D; De Pas, Tm | |
| Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study | 1-gen-2025 | Catania, C.; Liu, S. V.; Garassino, M.; Delmonte, A.; Scotti, V.; Cappuzzo, F.; Genova, C.; Russo, A.; Russano, M.; Bennati, C.; Colantonio, I.; Martini, S.; Pino, M.; Conforti, F.; Pala, L.; Minuti, G.; Citarella, F.; Olmetto, E.; Esposito, A.; Cascetta, P.; Di Lello, A.; De Pas, T. | |
| Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature | 1-gen-2021 | Pala, L; Conforti, F; Cocorocchio, E; Ferrucci, P; De Pas, Mt; Stucchi, S; Repetto, M; Saponara, M; Queirolo, P | |
| Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity | 1-gen-2018 | Rao, Gh; Kim, Ik; Conforti, F; Liu, J; Zhang, Yw; Giaccone, G | |
| Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19 | 1-gen-2020 | Pala, L; Conforti, F; Saponara, M; De Pas, T; Giugliano, F; Sale, Eo; Jemos, C; Rubatto, M; Agostini, A; Quaglino, P; Fava, P; Fierro, Mt; Queirolo, P | |
| Different Response to Immunotherapy According to Melanoma Histologic Subtype | 1-gen-2022 | Pala, L; Conforti, F; Pagan, E; Bagnardi, V; De Pas, Tm; Mazzarol, G; Barberis, M; Pennacchioli, E; Orsolini, G; Prestianni, P; Zagami, P; Nicolo', E; Patane, D; Saponara, M; Queirolo, P | |
| Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy | 1-gen-2022 | Corti, C; Conforti, F; Pala, L; Catania, C; Cocorocchio, E; Ferrucci, Pf; Curigliano, G; Queirolo, P; De Pas, T |